Onconetix Reports 78.9% Revenue Decline in Q1 2026, Net Loss Improves to $4.2 Million

Onconetix, Inc. reported a significant decline in financial performance for the first quarter of 2026, with revenues of $21,457, a decrease of 78.9% compared to $101,630 in the same period of 2025. The company attributed this drop primarily to reduced customer demand and timing of orders for its diagnostic product, Proclarix. The cost of revenue also decreased to $23,112 from $55,798, resulting in a gross loss of $1,655 for the quarter, contrasting with a gross profit of $45,832 in the previous year.

Operating expenses for the quarter totaled $10.2 million, down 19% from $12.6 million in the prior year. This reduction was driven by a decrease in impairment of goodwill, which fell to $8.1 million from $10.9 million. However, selling, general, and administrative expenses increased by 21.8% to $2.0 million, reflecting higher professional fees associated with regulatory and legal matters. The net loss for the quarter was $4.2 million, a 50.7% improvement from the $8.5 million loss reported in the same quarter of 2025.

Onconetix's operational developments included the acquisition of Proteomedix AG in December 2023, which brought Proclarix into its portfolio. The company has since shifted its focus from vaccine development to the commercialization of Proclarix, which is CE-marked and expected to generate revenue in the U.S. through a licensing agreement with LabCorp. The company is also pursuing a Share Exchange Agreement with Realbotix Corp., which could further enhance its market position.

As of March 31, 2026, Onconetix had cash reserves of approximately $3.7 million, down from $5.2 million at the end of 2025. The company reported a working capital surplus of $1.3 million but faces substantial doubt about its ability to continue as a going concern due to ongoing operating losses and the need for additional capital to fund operations. Management plans to pursue further equity or debt financing and expects to generate revenue from Proclarix sales to support its operations.

Looking ahead, Onconetix anticipates that the commercialization of Proclarix will help offset some operational expenses, although it expects to incur significant costs related to scaling up production and marketing efforts. The company remains focused on securing additional funding and successfully executing the Realbotix transaction to enhance its financial stability and growth prospects.